NCT06642792

A Study of AK129 With or Without AK117 in PD(L)1-refractory Classic Hodgkin Lymphoma

A Phase I/II Study of AK129 (Bispecific Antibody Targeting LAG-3 and PD-1) Monotherapy or in Combination With AK117 (Anti-CD47 Monoclonal Antibody) in Relapse or Refractory Classic Hodgkin Lymphoma With PD-1/L1 Inhibitor Treatment Failure

• Status: Recruiting
• Phase: Phase 1 / Phase 2
• Study type: Interventional
• Enrollment: 280 (estimated)
• Sponsor: Akeso · Industry
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

This is a phase I/II study. All subjects are patients diagnosed with relapse or refractory (R/R) classic Hodgkin lymphoma (cHL) and has progressed on treatment with PD-1/L1 inhibitor therapy. The purpose of this study is to evaluate the safety and efficacy of AK129 (bispecific antibody targeting LAG-3 and PD-1) monotherapy or in combination with AK117 (anti-CD47 monoclonal antibody) in R/R cHL with PD-1/L1 inhibitor treatment failure.

Conditions

• Classic Hodgkin Lymphoma

Interventions

Type	Name	Description
DRUG	AK129	Subjects receive AK129 intravenously.
DRUG	AK117	Subjects receive AK117 intravenously.

Timeline

• Start date: 2025-01-17
• Primary completion: 2027-11-01
• Completion: 2028-02-01
• First posted: 2024-10-15
• Last updated: 2025-02-11

Locations

1 site across 1 country: China